Regulatory News:
Under the liquidity contract signed between Cerenis Therapeutics (Paris:CEREN) and Gilbert Dupont, the following assets were booked to the liquidity account at 31st December 2016:
- Number of shares: 23,291
- Cash balance in the liquidity account: 204,687.69 €
As a reminder, in the last half-year report, at 30th June 2016, the liquidity account stood as follows:
- Number of shares: 26,242
- Cash balance in the liquidity account: 173,938.94 €
About Cerenis Therapeutics: www.cerenis.com
Cerenis
Therapeutics is an international biopharmaceutical company dedicated to
the discovery and development of innovative HDL therapies for the
treatment of cardiovascular and metabolic diseases. HDL is the primary
mediator of the reverse lipid transport, or RLT, the only natural
pathway by which excess cholesterol is removed from arteries and is
transported to the liver for elimination from the body.
Cerenis is
developing a portfolio of HDL therapies, including HDL mimetics for the
rapid regression of atherosclerotic plaque in high-risk patients such as
post-ACS patients and patients with genetic HDL deficiency, as well as
drugs which increase HDL for patients with a low number of HDL particles
to treat atherosclerosis and associated metabolic diseases including
Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic
Steato-Hepatitis (NASH).
Cerenis is well positioned to become one of the leaders in the HDL therapeutic market, with a broad portfolio of programs in development.
Since its inception in 2005, the company has been funded by top tier investors: Sofinnova Partners, HealthCap, Alta Partners, EDF Ventures, Daiwa Corporate Investment, TVM Capital, Orbimed, IRDI/IXO Private Equity and Bpifrance (Fund for Strategic Investment) and last March successfully completed an IPO on Euronext raising €53.4m.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170104006189/en/